Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

28.09.2023 - TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) - Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the ...

Related Keywords

Houston ,Texas ,United States ,Canada ,Toronto ,Ontario , ,Medicenna Therapeutics Corp ,Conference In Cancer Research ,Cancer Research ,Synergistically Engaging ,Bifunctional Superkine ,Medicenna Therapeutics Chart ,Edicenna Therapeutics Kurs ,Medicenna Therapeutics Aktie ,